|MDACC Study No:||2013-0624 (clinicaltrials.gov NCT No: NCT01985477)|
|Title:||Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma|
|Principal Investigator:||Jatin J. Shah|
|Treatment Agent:||ATRA; Dexamethasone; Revlimid|
|Study Description:||The goal of the Phase I portion of this clinical research study is to find the |
tolerated dose of the combination of lenalidomide, all-trans retinoic acid
(ATRA), and dexamethasone that can be given to patients with relapsed or
The goal of the Phase II portion of this study is to learn if ATRA when given
in combination with lenalidomide alone or with lenolidamide and dexamethasone
can help to control MM.
The safety of the drug combination will be studied in both phases.